Advancing Systemic Therapy in Gastric Cancer: Key Updates From the Korean Practice Guidelines for Gastric Cancer 2024

Overview

Journal J Gastric Cancer

Date 2025 Jan 17

PMID 39822169

Authors

Min-Hee Ryu

Keun Won Ryu

Affiliations

Soon will be listed here.

References

Shah M, Shitara K, Ajani J, Bang Y, Enzinger P, Ilson D . Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023; 29(8):2133-2141. PMC: 10427418. DOI: 10.1038/s41591-023-02465-7. View

Kang Y, Kim H, Yook J, Park Y, Lee J, Kim Y . Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY. J Clin Oncol. 2024; 42(25):2961-2965. DOI: 10.1200/JCO.23.02167. View

. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer. 2019; 19(1):1-48. PMC: 6441770. DOI: 10.5230/jgc.2019.19.e8. View

Janjigian Y, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges J . Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023; 402(10418):2197-2208. DOI: 10.1016/S0140-6736(23)02033-0. View

Kim I, Kang S, Choi W, Seo A, Eom B, Kang B . Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline). J Gastric Cancer. 2025; 25(1):5-114. PMC: 11739648. DOI: 10.5230/jgc.2025.25.e11. View

Shitara K, Lordick F, Bang Y, Enzinger P, Ilson D, Shah M . Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3.... Lancet. 2023; 401(10389):1655-1668. DOI: 10.1016/S0140-6736(23)00620-7. View

Kim T, Kim I, Kang S, Choi M, Kim B, Eom B . Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach. J Gastric Cancer. 2023; 23(1):3-106. PMC: 9911619. DOI: 10.5230/jgc.2023.23.e11. View

Etoh T, Ohyama T, Sakuramoto S, Tsuji T, Lee S, Yoshida K . Five-Year Survival Outcomes of Laparoscopy-Assisted vs Open Distal Gastrectomy for Advanced Gastric Cancer: The JLSSG0901 Randomized Clinical Trial. JAMA Surg. 2023; 158(5):445-454. PMC: 10018406. DOI: 10.1001/jamasurg.2023.0096. View

Lee J, Kim J, Jung H, Kim J, Jeong W, Jeon T . Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer. 2014; 14(2):87-104. PMC: 4105383. DOI: 10.5230/jgc.2014.14.2.87. View

10.

Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z . Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label,.... Lancet Oncol. 2021; 22(8):1081-1092. DOI: 10.1016/S1470-2045(21)00297-7. View

11.

Rha S, Oh D, Yanez P, Bai Y, Ryu M, Lee J . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023; 24(11):1181-1195. DOI: 10.1016/S1470-2045(23)00515-6. View